How To Prevent GVHD in Allogenic HSCT?

By Blood Cancer Talks - Last Updated: January 24, 2024

In the latest episode of Blood Cancer Talks, Shernan Holtan, MD, of the University of Minnesota, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; for a conversation on graft versus host disease (GVHD) prophylaxis in allogenic hematopoietic stem cell transplantation (HSCT).

Dr. Holtan and the hosts explored recent data on post-transplant cyclophosphamide and abatacept, including the BMT CTN 1203 trial. This trial studied three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for the prevention of GVHD with allogenic HSCT.

Another key trial discussed was BMT CTN 1703, which studied experimental prophylaxis (tacrolimus, mycophenolate mofetil, and cyclophosphamide) versus standard prophylaxis (tacrolimus plus methotrexate).

This podcast originally appeared on Blood Cancer Talks.

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

How To Prevent GVHD in Allogenic HSCT?

Related